Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

/PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...

Related Keywords

United States ,San Antonio ,Texas ,New Jersey ,East Hanover ,America ,Julie Masow ,Jamie Bennett ,Sloan Simpson ,Prnewswire Novartis ,Virtual Scientific Program ,Twitter ,Novartis ,Exchange Commission ,Novartis Pharmaceuticals ,Novartis Pharmaceuticals Corporation ,Nj Novartis Pharmaceuticals Corporation ,Cancer Genome Atlas Network ,University Of California San Francisco ,Novartis Pharmaceuticals Corp ,Helen Diller Family Comprehensive Cancer Center ,Antonio Breast Cancer Symposium ,Breast Oncology ,Clinical Trials Education ,California San Francisco ,Helen Diller Family Comprehensive Cancer ,Scientific Program ,Prescribing Information ,Advanced Breast ,Pharmaceuticals Corporation ,San Antonio Breast Cancer Symposium ,Cancer Genome Atlas ,Aromatase Inhibitor Resistance ,Circulating Tumour ,Metastatic Breast ,Alpelisib Plus Fulvestrant ,Participants With ,Advanced Breast Cancer After Treatment With ,Aromatase Inhibitor ,Study Assessing ,Subjects With Advanced ,Carry Either ,Two Part ,Placebo Controlled Study ,Combination With Trastuzumab ,Maintenance Therapy ,Patients With ,Advanced Breast Cancer With ,Alpelisib Plus Olaparib ,High Grade Serous Ovarian Cancer ,